Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 4, 2004 - Issue 6
Submit an article Journal homepage
194
Views
24
CrossRef citations to date
0
Altmetric
Review

Therapeutic potential of targeting IL-1 and IL-18 in inflammation

Martin Braddock AstraZeneca R&D Charnwood, Disease Sciences Section, Discovery Bioscience Department, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK. [email protected]
,
Anthony Quinn AstraZeneca R&D Charnwood, Disease Sciences Section, Department of Experimental Medicine, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK
&
Jan Canvin AstraZeneca R&D Charnwood, Disease Sciences Section, Department of Experimental Medicine, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK
Pages 847-860 | Published online: 23 Feb 2005

Bibliography

  • BIRD S, ZOU J, WANG T, MUNDAY B, CUNNINGHAM C, SECOMBES CJ: Evolution of IL- l3. Cytokine Growth Factor Rev (2002) 13:483–502.
  • •A complete review of IL-113.
  • GRACIE JA, ROBERTSON SE, MCINNES IB: Interleuldn-18. j Leukoc. Biol. (2003) 73:213–224.
  • ••A comprehensive review of IL-18.
  • SIMS JE: IL-1 and IL-18 receptors, and their extended family. Carr: Opin. Immunol (2002) 14:117–121.
  • ••An overview of the IL-1 superfarnily.
  • AREND WP, MALYAK M, GUTHRIDGE CJ, GABAY C: Interleuldn-1 receptor antagonist: role in biology. Annu. Rev. Immunol (1998) 16:27–55.
  • HALLEGUA DS, WEISMAN MH: Potential therapeutic uses of interleukin-1 receptor antagonists in human diseases. Ann. Rheum. Dis. (2003) 61:960–967.
  • COMINELLI F, PIZARRO TT: Interleuldn-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Ailment. Pharmacol The]: (1996) 10:49–53.
  • ROTHWELL NJ: Interleuldn-1 and neuronal injury: mechanisms, modification and therapeutic potential. Brain Behav. Immun. (2003) 17:152–157.
  • DAYERJM: The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine (2002) 69:123–132.
  • •A comparison of TNF-a and IL-113.
  • GRACIE JA, FORSEY RJ, CHAN WL et al.: A pro-inflammatory role for IL-18 in rheumatoid arthritis. J Clin. Invest. (1999) 104:1393–1401.
  • UDAGAWA N, HORWOOD NJ, ELLIOTT J et al.: Interlekin-18 (interferon-gamma inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon gamma to inhibit osteoclast formation. Exp. Med. (1997) 185:1005–1012.
  • CHIKANZA IC, ROUX-LOMBRAD P, DAYERJM, PANAYI GS: Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritic Rheum. (1995) 38:642–648.
  • CASINI-RAGGI V, KAM L, CHONG YJ,FIOCCHI C, PIZARRO TT, COMINELLI F: Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol (1995) 154:2434–2440.
  • EASTGATE JA, SYMONS JA, WOOD NC, GRINLINTON FM, DI GIOVINE FS, DUFF GW: Correlation of plasma interleuldn-1 levels with disease activity in rheumatoid arthritis. Lancet (1988) 2:706–708.
  • ROONEY M, SYMONS JA, DUFF GW: Interleuldn-1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol hat. (1990) 10:217–219.
  • DENTENER MA, CREUTZBERG EC, SCHOLS AM et al.: Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax (2001) 56:721–726.
  • ISAACS KL, SARTOR RB, HASKILL JS:Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterol (1992) 103:1587–1595.
  • FIRESTEIN GS, BERGER AE, TRACEY DE et al.: IL-1 receptor antagonist production and gene expression in rheumatoid arthritis and osteoarthritis synovium. Arthritic Rheum. (1992) 149:1054–1062.
  • KAHLE P, SAAL JG, SCHAUDT K, ZACHERJ, FRITZ P, PAWELEC G: Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial fluid. Ann. Rheum. Dis. (1992) 51:731–734.
  • KOCH AE, KUNKEL SL, CHENSUE SW, HAINES GK, STREITER RIVI: Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Gin. Immunol Immunopath. (1992) 65:23–29.
  • NOURI AM, PANAYI GS, GOODMAN SM: Cytokines and the chronic inflammation of inflammatory disease. I. The presence of interleuldn-1 in synovial fluids. Clin. Exp. Immunol (1984) 55:295–302.
  • CHUNG KF: Cytokines in chronic obstructive pulmonary disease. Eui: RespiL J (2001) 18\(Suppl. 34):50s–59s.
  • BROIDE DH, LOTZ M, CUOMO AJ, COBURN DA, FEDERMAN EC, WASSERIVIAN SI: Cytokines in symptomatic asthma airways. J. Allergy Immunol (1992) 89:958–967.
  • SOUSA AR, LANE SJ, NAKHOSTEEN JA, LEE TH, POSTON RN: Expression of interleuldn-1 beta (IL-1I3) and interleuldn-1 receptor antagonist (IL-1Ra) on asthmatic bronchial epithelium. Am. J. Respic Crit. Care Med. (1996) 154:1061–1066.
  • POMERANTZ BJ, REZNIKOV LL, HARKEN AH, DINARELLO CA: Inhibition of caspase I reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1I3. Proc. Natl. Acad. ScL USA (2001) 98:2871–2876.
  • PEARCE WH, SWEIS I, YAO JS, MCCARTHY WJ, KOCH AE: Interleuldn-113 and tumour necrosis factor-alpha release in normal and diseased human infrarenal aortas.Vasc. Snag. (1992)16:784–789.
  • LOMBARDI VR, GARCIA M, REY L CACABELOS RR: Characterisation of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy Alzheimer's disease individuals. Neuroimmunol (1999) 97:163–171.
  • GRIFFIN WS, MRAK RE: Interleuldn-1 inthe genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc. Biol. (2002) 72:233–238.
  • SHENG JG, MRAK RE, GRIFFIN WS: Interleuldn-1 expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution. Neuropathol Appl. Nerobiol (1995) 21:290–301.
  • BASU A, KRADY JK, O'MALLEY M, STYREN SD, DEKOSKY ST, LEVISON SW: The type 1 interleuldn-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. Neunosci. (2002) 22.6071–6082.
  • CALKINS CM, BENSARD DD, SHAMES BD et al: IL-1 regulates in vivo C-X-C chemokine induction and
  • ••
  • •• neutrophil sequestration following endotoxemia. Endotox. Res. (2002) 8:59–67.
  • PRUITT JH, COPELAND EM III, MOLDOWER LL: Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome and septic shock. Shock (1995) 3:235–251.
  • DEN BROEDER AA, JOOSTEN LA, SAXNE T et al.: Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis. (2002) 61:311–318.
  • BRESNIHAN B, ROUX-LOMBARD P, MURPHY E, KANE D, FITZGERALD 0, DAYER JM: Serum interleukin-18 and interleukin 18 binding protein in rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61:726–729.
  • URAUSHIHARA KT, TOTSUKA T, OKAZAWA A et al: Macrophage-derived IL-18 targeting for the treatment of Crohn's disease. Carr. Drug Targets Inflarnm. (2003) 2:131–136.
  • PIETRZAK A, LECEWICZ-TORUN B, CHODOROWSKA G, ROLINSKI J: Interleukin-18 levels in the plasma of psoriatic patients correlate with the extent of skin lesions and the PASI score. Acta Dermato-Venerologica (2003) 83:262–265.
  • FUKAURA H, KIKUCHI S: IL-18 in multiple sclerosis. Nippon Rinsho (lap. I Clin. Med) (2003) 61:1416–1421.
  • MALLAT Z, CORBAZ A, SCOAZEC A et al.: Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation (2001) 104: 1598-1603.
  • GERDES N, SUKHOVA GK, LIBBY P et al.: Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells and macrophages: implications for atherogenesis. J. Exp. Med. (2002) 90:E34–E38.
  • BLANKENBERG S, TIRET L, BICKEL C et al.: Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation (2002) 106:24–30.
  • ••IL-18 is a possible biomarker forcardiovascular death.
  • JOOSTEN LA, RADSTAKE TR, LUBBERTS E et al: Association of interleukin-18 expression with enhanced levels of both interleukin-113 and tumour necrosis factor a in knee synovial tissue of patients with rheumatoid arthritis. Arhritis Rheum. (2003) 48:339–347.
  • OKAMURA H, TSUTSI H, KOMATSU T et al.: Cloning of a new cytokine that induces IFN-gamma production bt T-cells. Nature (1995) 378:88–91.
  • YOSHIMOTO T, TAKEDA K, TANAKA T et al.: IL-12 up-regulates IL-18 receptor expression on T cells, Thl cells and B cells: synergism with IL-18 for IFN-gamma production.). Immunol (1998) 161:3400–3407.
  • MICALLEF MJ, OHTSUKI T, KOHNO K et al.: Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eui: Immunol (1996) 26: 1647-1651.
  • DAO T, MEHAL WZ, CRISPE IN: IL-18augments perforin-dependent cytotoxicity of liver NK-T cells. J. Immunol. (1998) 161:2217–2222.
  • MUNDER M, MALLO M, EICHMANN K, MOD OLELL M: Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway for autocrine macrophage activation. J. Exp. Med. (1998) 187:2103–2108.
  • TAKEDA K, TSUTSI H, YOSHIMOTO T et al.: Defective NK cell activity and Thl response in IL-18 deficient mice. Immunity (1998) 8:383–390.
  • OLEE T, HASHIMOTO S, QUACH J, LOTZ M: IL-18 is produced by articular chondrocytes and induces pro-inflammatory and catabolic responses. J.Immunol. (1999) 162:1096–1100.
  • JOOSTEN LA, VAN DE LOO FA, LUBBERTS E et al.: An IFN-gamma- independent pro-inflammatory role of IL-18 in murine streptococcal cell wall arthritis. I Immunol. (2000) 165:6553–6558.
  • WEI XQ, LEUNG BP, ARTHUR HM, MCINNES IB, LIEW FY: Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis in mice lacking IL-18. IrnmunoL (2001) 166:517–521.
  • NOVICK D, KIM S-H, FANTUZZI G, REZNIKOV L, DINARELLO C, RUBINSTEIN M: Interleukin-18 binding protein: a novel modulator of the Thl cytokine response. Immunity (1999) 10:127-136. The discovery of IL–18bp.
  • BANDA NK, VONDRACEK A, KRAUS D et al.: Mechanism of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J. Immunol (2003) 170:2100–2105.
  • PLATER-ZYBERK C, JOOSTEN LA, HELSEN MM et al.: Therapeutic effect of neutralising endogenous IL-18 activity in the collagen-induced model of arthritis. Gin. Invest. (2001) 108:1825–1832.
  • •IL-18 plays a role in arthritis in viva
  • DINARELLO CA: Interleuldn-1 and interleukin-1 antagonsim. Blood (1991) 77: 1627-1652.
  • CERRETTI DP, KOZLOSKY CJ, MOSLEY B et al.: Molecular cloning of the interleukin-1 beta converting enzyme. Science (1992) 256:97–100.
  • THORNBERRY NA, BULL HG, CALAYCAY JR et al.: A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature (1992) 356:768–774.
  • KOBAYASHI Y, YAMAMOTO K, SAIDO T, KAWASAKI H, OPPENHEIM J, MATSUSHIMA K: Identification of a calcium-activated neutral protease as a processing enzyme of human interleukin-1 alpha. Proc. Nati Acad. Sci. USA (1990) 87:5548–5552.
  • WAKABAYASHI G, GELFAND J, JUNG W, CONNOLLY R, BURKE J, DINARELLO C: Staphlococcus epidennidis induces complement activation, tumour necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia - comparison to Escherichia coil Gin. Invest. (1991) 87:1925–1935.
  • GREENFEDER SA, NUNES P, KWEE L, LABOW M, CHIZZONITE RA, JU G: Molecular cloning and characterisation of a second subunit of the interleukin-1 receptor complex. J. Biol. Chem (1995) 270:13757–13765.
  • LIEGE S, LAYE S, LI K, MOZE E, NEVEU PJ: Interleukin-1 receptor accessory protein (IL-1RacP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1I3. Neuroimmunoi (2000) 110:134–139.
  • CASADIO R, FRIGIMELICA E, BOSSU P et al: Model of interaction of the IL-1 receptor accessory protein IL-1RacP with the IL-113/IL-1RI complex. FEBS Lett. (2001) 499:65–68.
  • SMEETS RL, VAN DE LOO FA, JOOSTEN LA et al.: Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritic Rheum. (2003) 48:2949–2958.
  • MUZIO M, NI J, FENG P, DIXIT VM: IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signalling. Science (1997) 278: 1612-1615.
  • BURNS K, MARTINON F, ESSLINGER C et al.: MyD88, an adapter protein involved in interleukin-1 signalling. Biol. Chem (1998) 273:12203–12209.
  • JANSSENS S, BEYAERT R: Functional diversity and regulation of different interleukin-1 receptor associated kinase (IRAK) family members. Ma Cell. (2003) 11:293–302.
  • ••Comprehensive review of IL-1 superfarnilysignalling pathways.
  • LUHESHI GN: Cytokines and fever. Mechanisms and sites of action. Ann. NY Acad. Sci (1998) 856:83–89.
  • VINCENTI MP, BRINCKERHOFF CE: Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-113. Arthritic Res. (2001) 3:381–388.
  • VAN DEN BERG WB, JOOSTEN LA, VAN DE LOO FA: TNF-a and IL-1I3 are separate targets in chronic arthritis. Clin. Exp. Rheumatol. (1999) 17:S105–S214.
  • MENGSHOL JA, VINCENTI MP, COON CI, BARCHOWSKY A, BRINCKERHOFF CE: Interleuldn-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritic Rheum. (2000) 43:801–811.
  • MCCACHREN SS, GREER PK, NIEDEL JE: Regulation of human synovial fibroblast collagenase messenger RNA by interleukin-1. Arthritic Rheum. (1989) 32:1539–1545.
  • BLANCO FJ, LOTZ M: IL-1 induced nitric oxide inhibits chondrocyte proliferation via PGE2. Exp. Cell Res. (1999) 218:319–325.
  • COLOTTA F, RE F, MUZIO M et al: Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science (1993) 261:472–475.
  • NEUMANN D, KOLLEWE C, MARTIN MU, BORASCHI D: The membrane form of the type II receptor accounts for inhibitory function. Immunol. (2000) 165:3350–3357.
  • •A functional role for IL-1RII.
  • ATTUR MG, DAVE MN, LEUNG MY et al.: Functional genomic analysis of type II IL-113 decoy receptor: potential for gene therapy in human arthritis and inflammation.j Immunol (2002) 168: 2001-2010.
  • BOURKE E, CASSETTI A, VILLA A, FADLON E, COLOTTA F, MANTOVANI A: IL-1I3 scavenging by the type II IL-1 decoy receptor in human neutrophils.j Immunol (2003) 170:5999–6005.
  • AREND WP: Interleuldn-1 receptor antagonist. Adv. Immunol (1999) 54:167–227.
  • GOUZE J-N, GOUZE E, PALMER GD et al.: A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer. Arthritic Res. The,: (2003) 5:R301–R309.
  • ABRAMSON SB, AMIN A: Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) (2002) 41:972–980.
  • AREND WP, WELGUS HG, THOMPSON RC, EISENBERG SP: Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. Clin. Invest. (1990) 85:1694–1697.
  • HORAI R, SAIJO S, TANIOKA H et al:Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin-1 receptor antagonist-deficient mice. Exp Merl (2000) 19:313-320. ao.FIRESTEIN GS, BOYLE DL, YU C et al: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. (1994) 37:644–653.
  • DINARELLO C: The role of interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl.). Med. (2000) 343:732–734.
  • SECKINGER P, KLEIN-NULEND J, ALANDER C, THOMPSON RC, DAYER JM, RAISZ LG: Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. I Immunol (1990) 145:4181–4184.
  • RUGGIERO P, BOSSU P, MACCHIA G et al.: Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type I and IL-1 receptor type II. J. Immunol (1997) 158:3881–3887.
  • VAN DE LOO FA, JOOSTEN LA, VAN LENT PL, ARNTZ 0J, VAN DEN BERG WB: Role of interleukin-1, tumour necrosis factor alpha and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymogen-induced arthritis. Arthritic Rheum. (1995) 38:164–172.
  • JOOSTEN LA, HELSEN MM, VAN DE LOO FA, VAN DEN BERG WB: Anticytokine treatment of established type-II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-tumour necrosis factor a, anti-interleukin-la/P and interleukin-1 receptor antagonist. Arthritic Rheum. (1996) 39:797–809.
  • DINARELLO CA: Targeting interleukin-18 with interleukin-18 binding protein. Ann. Rheum. Dis. (2000) 59 (Suppl. 1)117420.
  • WOOLEY PH, WHALEN JD, CHAPMAN DL et al.: The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritic Rheum. (1993) 36:1305–1315.
  • HENDERSON B, THOMPSON RC, HARDINGHAM T, LEWTHWAITE J: Inhibition of interleukin-1 induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine (1991) 2:246–249.
  • MATSUKAWA A, OHKAWARA S, MAEDA T, TAKAGI K, YOSHINAGA M: Production of IL-1 and IL-1 receptor antagonist and the pathological significance in lipopolysaccharide-induced arthritis in rabbits. Clin. Exp. Immunol (1993) 93:206–211.
  • ROESSLER BJ, HARTMANN JVV, VALLANCE DK, LATTA JM, JANICH SL, DAVIDSON BL: Inhibition of interleukin-1 induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector. Hum. Gene Ther (1995) 6:307–316.
  • BANDARA G, MUELLER GM, GALEA-LAURI J et al: Intra-articular expression of biologically active interleukin-1-receptor antagonist protein by ex vivo gene transfer. Proc. Natl. Acad. Sci. USA (1993) 90:10764–10768.
  • GEIGER T, TOWBIN H, COSENTI-VARGAS A et al.: Neutralization of interleukin-1 activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the acute-phase response. Clin. Exp. Rheumatol. (1993) 11:515–522.
  • BAKKER AC, JOOSTEN LA, ARNTZ OJet al.: Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum. (1997) 40:893–900.
  • MULLER-LANDER U, ROBERTS CR, FRANKLIN BN et al: Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. Immunol (1997) 158:3492–3498.
  • CAMPION GV, LESBACK ME, LOOKABAUGH J, GORDON G, CATALANO MA: Dose-range and dose-frequency of study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. (1996) 39:1092–1101.
  • ••A pivotal study of anakinra in humans.
  • BRESNIHAN B, ALVARO-GRACIA JM,COBBY M et al.: Treatment of rheumatoid arthritis with recombinant interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196–2204.
  • JIANG Y, GENANT HK, WATT let al.:A multi-centre, double-blind, dose ranging, randomised, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation with Genant and Larsen scores. Arthritis Rheum. (2000) 43:1001–1009.
  • BENDELE A, SENNELLO G, MCABEE T, FRAZIER J, CHLIPALA E, RICH B: Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats. Rheumatol (1999) 26:1225–1229.
  • BENDELE AM, CHLIPALA ES, SCHERRER J et al.: Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumour necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum. (2000) 43:2648–2659.
  • FELGE U, HU YL, GASSER J, CAMPAGNUOLO G, MUNYAKAZI L, BOLON B: Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats. Mol. Life Sci. (2000) 57:1457–1470.
  • COHEN S, HURD E, CUSH J et al: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:614–624.
  • ••A key study of combination therapy -anakinra with MTX.
  • LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl. Med. (2000) 343:1594–602.
  • SCHIFF MH, BULPITT K, WEAVER AA et al.: Safety of combination therapy with Anakinra and Etanercept in patients with rheumatoid arthritis. Arthritis Rheum. (2001) 44:s79.
  • •An abstract on safety issues in combination therapy - anakinra with etanercept.
  • ROONEY T, MADIGAN A, GREENAN L et al.: Combination therapy with anakinra and PEGylated soluble tumor necrosis factor receptor type I (Pegsunercept) in rheumatoid arthritis (RA): preliminary analysis of clinical, functional, synovial tissue, and radiographic outcomes from a Phase II, open-label, mode of action study. Arthritic Rheum. (2003) 48:s124.
  • BRESNIHAN B, CUNNANE G: Infection complications associated with the use of biologic agents. Rheum. Dis. Clin.
  • North Am. (2003) 29:185–202.
  • ••A comprehensive overview of clinical risksassociated with administration of biologicals to patients with RA.
  • MOHAN AK, COTE TR, SIEGEL JN, BRAUN MM: Infectious complications of biologic treatments of rheumatoid arthritis. Carr. Opin. Rheumatol. (2003) 15:179–184.
  • ••A comprehensive overview of clinical risksassociated with administration of biologicals to patients with RA.
  • FLEISCHMANN RIVI, SCHECHTMAN J, BENNETT R et al.: Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-lra) in patients with rheumatoid arthritis. A large, international, multi-centre, placebo-controlled trial. Arthritis Rheum. (2003) 48:927–934.
  • FUKUMOTO T, MATSUKAWA A, OHKAWARA S, TAKAGI K, YOSHNIAGA M: Administration of neutralizing antibody against rabbit IL-1 receptor antagonist exacerbates lipopolysaccharide-induced arthritis in rabbits. Inflamm. Res. (1996) 45:479–485.
  • MAY, THORNTON S, BOIVIN GP, HIRSH D, HIRSCH R, HIRSCH E: Altered susceptibility to collagen induced arthritis in transgenic mice with aberrant expression of IL-1 receptor antagonist. Arthritis Rheum. (1998) 41:1798–1805.
  • BENDELE A, MCABEE T, SENNELLO G, FRAZIER J, CHLIPALA E, MCCABE D: Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum. (1999) 42:498–506.
  • HAWKINS PN, LACHMANN HJ, AGANNA E, MCDERMOTT MF: Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. (2004) 50:607–612.
  • LOVELL DJ, BOWYER SL: Treatment of neonatal onset multisystem inflammatory disease (NOMID) with IL-1 RA (Anakinra). Arthritis Rheum. (2003) 48:S517.
  • GOUPILLE P, GIRAUBEAU B, CONROZIER T, MARLIERE J, KIEFER P, CHEVALIER X: Safety and efficacy of intra-articular injection of IL-1Ra (I1-1 receptor antagonist) in patients with painful arthritis of the knee: a multi-centre, double blind study. Arthritis Rheum. (2003) 48(Suppl.):S696.
  • •Abstract describing a preliminary study of anakinra in patients with OA.
  • GABAY C: IL-1 trap Regeneron/Novartis. Carr. Opin. Invest. Drugs. (2003) 4:593–597.
  • ECONOMIDES AN, CARPENTER LR, RUDGE JS et al.: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. (2003) 9:47–52.
  • GULER H-P, CALDWELL J, LITTLEJOHN T III, MCILWAIN H, OFFENBERG H, STAHL N: A Phase I, single dose escalation study of IL-1 trap in patients with rheumatoid arthritis. Arthritis Rheum. (2001) 44:s370.
  • CALDWELL J, OFFENBERG H, AGOSTI J et al.: Results of a Phase I safety and pharmacokinetic study of interleukin-1 receptor in rheumatoid arthritis. EULAR (2002) Abstract FRI0098.
  • VEZINA CJ, CHEN C, HUANG H et al: Characterisation of fully human monoclonal antibodies to human interleukin-1 receptor type I that inhibit interleukin-1 signalling. Arthritis Rheum. (2003) 48:S280.
  • SMEETS RL, VAN DE LOO FA, JOOSTEN LA et al.: Modulation of arthritis through overexpression of soluble interleukin-1 receptor accessory protein (sIL-1RacP): a novel inhibitor of interleukin-1 distinct from IL-1Ra. Arthritis Rheum. (2003) 48:S152. Website

Websites

  • http://www.regeneron.com/investor/ press_detail.asp?v_c_id=184 Data on file Regeneron Pharmaceuticals.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.